 |
PRESS
RELEASES 
|
Ad-hoc Release
Mologen successfully carries out a capital increase
• Placement volume of EUR 2.8 million
The Executive Board of MOLOGEN AG finalized a capital increase for contributions in cash with the exclusion of the subscription right on March 27, 2009 and prepared to record this in the register of companies. Based on a resolution by the annual general meeting and approval by the Supervisory Board of Mologen AG, a total of 425,000 ordinary bearer shares (approximately 4.5% of the ordinary share capital) were placed with institutional investors. At an issuing price of EUR 6.50 per share, this provides the Company with cash totaling approximately EUR 2.8 million. The ordinary share capital of Mologen AG has thus increased from EUR 9,378,348 to EUR 9,803,348. Mologen AG has managed to successfully carry out a capital increase in an extremely difficult stock market environment and win over new investors. The new shares were subscribed at a premium to the current share price. The proceeds will be used specifically for the further development of the product pipeline.
About MOLOGEN
MOLOGEN AG, a biopharmaceutical company based in Berlin, specializes in the research and development of innovative medicines based on DNA structures (DNA: deoxyribonucleic acid).
Its patented DNA-based technology platforms MIDGE® and dSLIM® form a universal foundation with a wide range of possible applications. Activities focus on product developments for the treatment of cancer and vaccines for serious infections in humans and animals.
MOLOGEN was founded in 1998 and was the first German biotechnology company to go public. MOLOGEN AG shares are listed in the General Standard of Deutsche Börse (ISIN DE 0006637200).
Disclaimer concerning prognoses
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.
|
|
